which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...
The latter drug was filed for approval in the UK in July for the treatment of mild cognitive impairment and mild to moderate Alzheimer's. Applied Therapeutics gets a warning letter from the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results